This program studied a novel Gene Coding™ approach that is designed to turn on, turn off, or modify the function of any gene in the genome. In CF, this approach sought to insert a large piece of healthy CFTR DNA at a precise location within the CFTR gene, which could enable the expression of a functional CFTR protein in essentially all individuals with CF, regardless of their individual mutation.

Status

No further development in CF is planned at this time.

Sponsor

This program was sponsored by SalioGen Therapeutics and partially funded by the Cystic Fibrosis Foundation.